<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892772</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000421</org_study_id>
    <nct_id>NCT03892772</nct_id>
  </id_info>
  <brief_title>Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea</brief_title>
  <acronym>ComboPlus</acronym>
  <official_title>Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apnimed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, there is no pharmacological intervention for OSA that targets multiple&#xD;
      pathophysiological deficits in combination. Here the investigators study the effect on sleep&#xD;
      apnea severity of combinations of pharmacological agents that stimulate the pharyngeal&#xD;
      muscles, stabilize ventilatory control, and increase the arousal threshold.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of the current study is to determine the effect of combination therapy&#xD;
      targeting phenotypic traits on OSA severity. Specifically, the investigators will assess the&#xD;
      effect of combination pharmacological therapy on OSA severity as measured by the&#xD;
      apnea-hypopnea index and the arousal index (co-primary outcome variables).&#xD;
&#xD;
      The investigators will also estimate the effects of the interventions on the physiological&#xD;
      traits responsible for OSA using polysomnography, namely:&#xD;
&#xD;
        -  Pharyngeal anatomy and its propensity towards collapse&#xD;
&#xD;
        -  The ability of the upper airway dilator muscles to activate and reopen the airway during&#xD;
           sleep (i.e. neuromuscular compensation)&#xD;
&#xD;
        -  Arousal threshold from sleep (i.e. the propensity for hypopneas/apneas to lead to&#xD;
           arousal and fragmented sleep).&#xD;
&#xD;
        -  Stability of the ventilatory control system feedback loop (i.e. loop gain). Baseline&#xD;
           traits will be used to examine whether patient characteristics influence the responses&#xD;
           to each combination of interventions (i.e. muscles, muscles plus loop gain, muscles plus&#xD;
           arousal threshold).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea-hypopnea index [AHI]</measure>
    <time_frame>3 days</time_frame>
    <description>Apneas and hypopneas per hour (3% desat and/or arousal), % change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoxic Burden</measure>
    <time_frame>3 days</time_frame>
    <description>Desaturation area under curve Ã— event frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arousal Index</measure>
    <time_frame>3 days</time_frame>
    <description>Number of arousals per hour (&gt;=3-sec), % change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale for Sleep Quality</measure>
    <time_frame>3 days</time_frame>
    <description>Sleep Quality 0-10 scale, 0 worst sleep quality, 10 best sleep quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale for Waking Unrefreshed</measure>
    <time_frame>3 days</time_frame>
    <description>Waking Unrefreshed 0-10 scale, 0 extremely refreshed, 10 extremely unrefreshed</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Visual Analog Scale for Excessive Fatigue</measure>
    <time_frame>3 days</time_frame>
    <description>Excessive Fatigue 0-10 scale, 0 no fatigue, 10 highly fatigued</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual Analog Scale for Low Energy</measure>
    <time_frame>3 days</time_frame>
    <description>Low Energy 0-10 scale, 0 no trouble with energy, 10 extremely low energy</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual Analog Scale for Treatment Satisfaction</measure>
    <time_frame>3 days</time_frame>
    <description>Treatment Satisfaction 0-10 scale, 0 extremely dissatisfied, 10 extremely satisfied</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Total Sleep Time in non-REM Stage 1</measure>
    <time_frame>3 days</time_frame>
    <description>% Total sleep time</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>SAS0421a, SAS0421b and SAS0421c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take SAS0421a, SAS0421b and SAS0421c for 3 days. Half doses will be given on the first night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAS0421a and SAS0421b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take SAS0421a and SAS0421b for 3 days. Half doses will be given on the first night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAS0421c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take SAS0421c for 3 days. Half doses will be given on the first night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take placebos for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAS0421a</intervention_name>
    <description>treatment will be given for 3 days</description>
    <arm_group_label>SAS0421a and SAS0421b</arm_group_label>
    <arm_group_label>SAS0421a, SAS0421b and SAS0421c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAS0421b</intervention_name>
    <description>treatment will be given for 3 days</description>
    <arm_group_label>SAS0421a and SAS0421b</arm_group_label>
    <arm_group_label>SAS0421a, SAS0421b and SAS0421c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAS0421c</intervention_name>
    <description>treatment will be given for 3 days</description>
    <arm_group_label>SAS0421a, SAS0421b and SAS0421c</arm_group_label>
    <arm_group_label>SAS0421c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo will be given for 3 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Ages 18 - 79 years&#xD;
&#xD;
          -  Suspected or diagnosed OSA&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any uncontrolled medical condition&#xD;
&#xD;
          -  Current use of the medications under investigation&#xD;
&#xD;
          -  Use of medications expected to stimulate or depress respiration (including opioids,&#xD;
             barbiturates, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).&#xD;
&#xD;
          -  Current use of hypnotic medications (trazodone, eszopiclone, benzodiazepines).&#xD;
&#xD;
          -  Current use of SNRIs/SSRIs or anticholinergic medications.&#xD;
&#xD;
          -  Conditions likely to affect obstructive sleep apnea physiology: neuromuscular disease&#xD;
             or other major neurological disorder, heart failure (also below), or any other&#xD;
             unstable major medical condition.&#xD;
&#xD;
          -  Respiratory disorders other than sleep disordered breathing:&#xD;
&#xD;
        chronic hypoventilation/hypoxemia (awake SaO2 &lt; 92% by oximetry) due to chronic obstructive&#xD;
        pulmonary disease or other respiratory conditions.&#xD;
&#xD;
          -  Other sleep disorders: periodic limb movements (periodic limb movement arousal index &gt;&#xD;
             10/hr), narcolepsy, or parasomnias.&#xD;
&#xD;
          -  Contraindications for SAS0421a and SAS0421b, including:&#xD;
&#xD;
               -  hypersensitivity to SAS0421a and SAS0421b (angioedema or urticaria)&#xD;
&#xD;
               -  pheochromocytoma&#xD;
&#xD;
               -  use of monoamine oxidase inhibitors&#xD;
&#xD;
               -  benign prostatic hypertrophy, urinary retention&#xD;
&#xD;
               -  untreated narrow angle glaucoma&#xD;
&#xD;
               -  bipolar disorder, mania, psychosis&#xD;
&#xD;
               -  history of major depressive disorder (age&lt;24).&#xD;
&#xD;
               -  history of attempted suicide or suicidal ideation within one year prior to&#xD;
                  screening&#xD;
&#xD;
               -  clinically significant constipation, gastric retention&#xD;
&#xD;
               -  pre-existing seizure disorders&#xD;
&#xD;
               -  clinically-significant kidney disorders (eGFR&lt;60 ml/min/1.73m2)&#xD;
&#xD;
               -  clinically-significant liver disorders&#xD;
&#xD;
               -  clinically-significant cardiovascular conditions&#xD;
&#xD;
               -  severe hypertension (SBP&gt;180 mmHg or DBP&gt;110 mmHg measured at baseline)&#xD;
&#xD;
               -  cardiomyopathy (LVEF&lt;50%) or heart failure&#xD;
&#xD;
               -  advanced atherosclerosis&#xD;
&#xD;
               -  history of cerebrovascular events&#xD;
&#xD;
               -  history of cardiac arrhythmias e.g., atrial fibrillation, QT prolongation&#xD;
&#xD;
               -  other serious cardiac conditions that would raise the consequences of an increase&#xD;
                  in blood pressure or heart rate&#xD;
&#xD;
               -  myasthenia gravis&#xD;
&#xD;
               -  pregnancy/breast-feeding&#xD;
&#xD;
          -  Additional contraindications for SAS0421c, including:&#xD;
&#xD;
               -  Use more than 500 mg/day of Aspirin&#xD;
&#xD;
               -  Allergies to this drug class&#xD;
&#xD;
               -  Adrenocortical insufficiency&#xD;
&#xD;
               -  Low sodium or potassium&#xD;
&#xD;
               -  hyperchloremic acidosis&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott A Sands, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley A Edwards, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott A Sands, PhD</last_name>
    <phone>617-278-0911</phone>
    <email>sasands@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Hess</last_name>
      <phone>617-732-8976</phone>
      <email>lhess1@bwh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash University</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bradley A Edwards, PhD</last_name>
      <phone>+61 3 9905 0187</phone>
      <email>bradley.edwards@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley A Edwards, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Scott Aaron Sands</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will IPD be available? Yes What data will be shared? All IPD collected during the study, after deidentification.&#xD;
When will data be available? Immediately after publication. No end date. With whom? Researchers who provide a methodologically sound proposal. For what types of analyses? Any purpose.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Immediately after publication. No end date.</ipd_time_frame>
    <ipd_access_criteria>1-page proposals should be directed to Dr. Scott Sands (sasands@bwh.harvard.edu). To gain access, requestors will be asked to sign a data use agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

